Business Context and Reporting Period
TNF Pharmaceuticals, Inc. (TNFA) filed a Form 8-K on October 1, 2024, reporting a material definitive agreement and unregistered equity sales. The company is incorporated in Delaware and trades on the Nasdaq Capital Market.
Key Financial Metrics
- Capital Raised: $600,000 gross proceeds from a private placement.
- Shares Issued: 283,019 shares of common stock.
- Price Per Share: $2.12 (120% of the 30-day volume-weighted average price).
- Use of Proceeds: General corporate purposes and working capital.
- Debt/Liquidity: The filing does not provide specific data on total debt, cash flow, or liquidity ratios.
Material Changes
The primary material change is the entry into a Stock Purchase Agreement with Prevail Partners, LLC. A unique provision allows Prevail to pay the purchase price directly to Prevail InfoWorks, Inc., an affiliate, to satisfy outstanding invoices from a Master Services and Technology Agreement dated August 23, 2024.
Outlook, Risks, and Commentary
- Transaction Status: The private placement is exempt from registration under Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D.
- Investor Status: Prevail Partners, LLC represented itself as an accredited investor acquiring shares for investment only.
- Risks: The filing notes that the securities are not registered and cannot be resold without registration or an applicable exemption.
Investor Verification Checklist
- Verify the exact amount of outstanding invoices owed to Prevail InfoWorks, Inc. to understand the net cash impact of the transaction.
- Confirm the current cash balance and burn rate to assess the sufficiency of the $600,000 raise for working capital needs.
- Review the full text of the Stock Purchase Agreement (Exhibit 10.1) for any additional covenants or restrictions.
- Check subsequent filings for any changes in the company's capitalization table or dilution effects.